background: cell mediated immunity, especially cytotoxic t cell responses against hiv-1 infection, plays a critical role in controlling viral replication and disease progres-sion. dna vaccine is a novel technology which is known to stimulate strong cellular immune responses. many dna vaccines have been tested for hiv infection but there is still no effective vaccine against this infection. cons...

Background: Cell mediated immunity, especially cytotoxic T cell responses against HIV-1 infection, plays a critical role in controlling viral replication and disease progres-sion. DNA vaccine is a novel technology which is known to stimulate strong cellular immune responses. Many DNA vaccines have been tested for HIV infection but there is still no effective vaccine against this infection. Cons...

objective: the global hiv epidemic continues to expand and exceeding previous predictions. an effective vaccine represents the best hope to curtail the hiv epidemic. dna vaccines induce humoral and cellular responses and mimic live vaccines without their pathogenic potential. the importance of cd8+ ctl responses in controlling hiv and siv viremia has led to production of a series of vaccine can...

Background: Development of an effective vaccine is highly needed in order to restrict the AIDS pandemic. DNA vaccines initiate both arms of immunity without the potential of causing disease. HIV-1 p24 and gp41 (gag and env) proteins play important roles in viral pathogenesis and are effective candidates for immune induction and vaccine design. Objective: In this study, new DNA vaccine candidate...

In this placebo-controlled phase II randomized clinical trial, we evaluated the safety and immunogenicity of a therapeutic prime-boost vaccine strategy using recombinant DNA (GTU-MultiHIV B clade) followed by boost vaccination with lipopeptide (HIV-LIPO-5) in HIV-infected patients on combined antiretroviral therapy. We show here that is well tolerated, consistently previous studies HIV-1-infect...

background: development of an effective vaccine is highly needed in order to restrict the aids pandemic. dna vaccines initiate both arms of immunity without the potential of causing disease. hiv-1 p24 and gp41 (gag and env) proteins play important roles in viral pathogenesis and are effective candidates for immune induction and vaccine design. objective: in this study, new dna vaccine candidate...

BACKGROUND We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines. METHODS Healthy HIV-uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity of (1) a 4-dose regimen of a DNA vaccine, (2) a 3-dose priming regimen of the DNA vaccine with a booster dose of an adeno...

UNLABELLED The search for an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine remains a pressing need. The moderate success of the RV144 Thai clinical vaccine trial suggested that vaccine-induced HIV-1-specific antibodies can reduce the risk of HIV-1 infection. We have made several improvements to the DNA platform and have previously shown that improved DNA vaccines alone are cap...

BACKGROUND We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C, given alone or as boost following a DNA plasmid vaccine expressing the same HIV-1 proteins plus Nef, in 114 healthy HIV-uninfected African adults. METHODOLOGY/PR...